Diagnosis and management of synovial sarcoma
Journal of Surgical Oncology2008Vol. 97(4), pp. 314–320
Citations Over TimeTop 10% of 2008 papers
Abstract
Synovial sarcoma accounts about 9% of soft tissue sarcomas, most commonly develops in the extremity of young adults, is considered high grade and contains a characteristic translocation (X;18;p11;q11). While surgery and radiation therapy have achieved excellent local control, distant metastasis remains the principal problem limiting survival. Although ifosfamide based chemotherapy has been associated with an improved survival in patients with synovial sarcoma, the search for less toxic and more targeted systemic therapies is ongoing.
Related Papers
- → Highly malignant soft tissue sarcoma of the extremity with a delayed diagnosis(2010)37 cited
- → Inflammatory Surrogate Parameters for Predicting Ifosfamide-Induced Neurotoxicity in Sarcoma Patients(2022)3 cited
- → A phase I–II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma(1988)40 cited
- → 67P Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced soft tissue sarcoma: A single-arm phase II trial(2021)2 cited
- → Single-Agent Doxorubicin versus Doxorubicin Plus Ifosfamide in Advanced Soft Tissue Sarcoma(2012)